Bonraybio Valuation
Is 6955 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6955 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6955's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6955's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6955?
Key metric: As 6955 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 6955's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | NT$0 |
| Market Cap | NT$2.73b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 6955's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.1x | ||
6704 Gwo Xi Stem Cell Applied Technology | 3.9x | n/a | NT$2.7b |
4132 Golden Biotechnology | 11.2x | n/a | NT$2.7b |
4168 GlycoNex Incorporation | 2.4x | n/a | NT$2.7b |
6808 3D Global Biotech | 6.9x | n/a | NT$3.1b |
6955 Bonraybio | n/a | n/a | NT$2.7b |
Price-To-Book vs Peers: Insufficient data to calculate 6955's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does 6955's PB Ratio compare vs other companies in the TW Biotechs Industry?
| 0 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: Insufficient data to calculate 6955's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is 6955's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 6955's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
RBC Bioscience
NT$254.3m
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.
6848
NT$19.60
7D
-0.5%
1Y
29.8%
Winston Medical Supply
NT$1.6b
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.
6817
NT$88.30
7D
-1.6%
1Y
-13.4%
YungShin Global Holding
NT$15.4b
Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.
3705
NT$57.90
7D
8.2%
1Y
27.1%